|
Response to Hepatitis B Vaccine in HIV-Infected Patients
|
SH Afrasiabian   , K Hajibageri , V Esmaeil Nasab , N Esmaeil Nasab , SH Sayfi |
|
|
|
Abstract: (4545 Views) |
| Introduction & Objective: The risk of developing chronic hepatitis B virus (HBV) is 5% in general population but can reach up to 20% in HIV patients. The response rate to HBV vaccine in HIV infected patients is 23.8-56 percent. The aim of this study was to evaluate response of HIV-infected patients to 20 µg dose of recombinant HBV vaccine.
Materials & Methods: In this quasi experimental study, 51 subjects, sampled through census, were HIV patients who had HBsAg negative test in HIV/AIDS counseling and care center. Patients were vaccinated with 20 µg of recombinant HBV vaccine, IM at intervals of 0, 1 and 6 months. Response to the vaccine was checked 2 months after the last injection. Data were analyzed with SPSS software, using descriptive statistics and nonparametric tests.
Results: The mean age of the patients was 33.68±8.37 years. Two patients were female (3.9%) and 49 patients were male (96.1%). Mean of hepatitis B antibody level was 47.55±71.58 mIU/ml. The levels of antibody in different patients were as follow: 31 patients (60.8%) <10 mIU/ml and 20 patients (39.2%)> 10 mIU/ml. There was no significant correlation between antibody levels and CD4+ cell count (correlation coefficient = -0.191).
Conclusion: Response to hepatitis B vaccination is low in HIV infected patients. Conventional dose of HBV vaccine is not enough to get protective immunity. Therefore, two-fold dose of vaccine dose, repeat of conventional dose or increasing of interval administration of hepatitis B vaccine should be considered in future studies. |
|
| Keywords: Hepatitis B vaccine, HIV/AIDS Patients, CD4+ T Lymphocytes |
|
|
Full-Text [PDF 135 kb]
(1512 Downloads)
|
Type of Study: Research |
Subject:
Special
Received: 2015/06/2 | Accepted: 2015/06/2 | Published: 2015/06/2
|
|
|
|
|
|
